Members of India’s Covid Working Group don’t think so. 2 hours ago A health worker prepares to administer a dose of the Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine, at a vaccination centre in Mumbai on April 1. | Punit Paranjpe / AFP On May 13, when the Indian government increased the duration between two doses of the Covishield vaccine to 12 weeks-16 weeks from eight weeks-six weeks, it cited “real life evidences, particularly from UK”. The decision, according to members of India’s Covid Working Group that recommended it, was driven by studies that suggested that the first dose of the vaccine, developed by Oxford University and the British-Swedish company AstraZeneca, provided substantial protection.